Jennifer B. Damico, who serves as Senior Vice President and Controller at Pfizer Inc., has executed a transaction involving the sale of company equity. According to a recent regulatory filing, the disposal occurred on June 9, 2026. The specific details of the transaction indicate that 2,000 shares of Pfizer's common stock were liquidated. The execution price for these shares was recorded at $25.70 per unit. This pricing structure resulted in a total transaction value amounting to $51,400.
Market data indicates that Pfizer's stock is currently trading at $25.60. This current market price sits in close proximity to the price at which the shares were sold by Ms. Damico. Independent analysis from InvestingPro suggests that the pharmaceutical company may be trading at a valuation below its intrinsic worth at these current levels. The company supports a dividend yield of 6.72%, and its total market capitalization stands at $146 billion.
Following the completion of this sale, Ms. Damico retains a direct ownership position in 31,397 shares of Pfizer common stock. This insider activity provides a snapshot of executive portfolio management within a major pharmaceutical entity. The transaction is part of a broader context of corporate developments and financial evaluations affecting Pfizer.
In parallel with this insider transaction, Pfizer has received significant regulatory updates regarding its drug Hympavzi. The U.S. Food and Drug Administration has granted an expanded approval for the medication. This new approval extends to patients with hemophilia A or B who are 12 years of age or older and have developed inhibitors. Furthermore, the approval now encompasses pediatric patients between the ages of 6 and 11 years, regardless of inhibitor status. Concurrently, the European Commission has broadened the marketing authorization for Hympavzi to include patients aged 12 and older with hemophilia A or B who have developed inhibitors.
Analyst sentiment surrounding Pfizer has also seen recent adjustments. RBC Capital has upgraded the stock rating for Pfizer from Underperform to Sector Perform. This rating change cites a balanced risk-reward profile for the company. The firm has set a price target of $25.00 for the stock. In contrast, Cantor Fitzgerald and UBS have both maintained Neutral ratings on Pfizer. Both institutions have established a price target of $27.00. UBS specifically noted that Pfizer is awaiting the results of a Phase III cancer drug trial for Sigvotatug vedotin. The company expects to report results from this trial imminently.
These developments highlight the dynamic nature of Pfizer's product portfolio and financial outlook. The combination of insider trading activity, regulatory expansions, and analyst evaluations underscores the multifaceted environment in which the company operates. Investors and analysts continue to monitor these factors as they assess the company's trajectory within the pharmaceutical sector.